Main idea: Seven-dose treatment and four-dose treatment of allergic rhinitis are comparable in terms of safety and tolerability.
The aim of the study was to investigatesubcutaneous immunotherapy efficiency in treating allergic rhinoconjunctivitis and asthma but is still inconvenient when heavy schedules are used.
In this open-label, Phase II trial, 130 adults were randomized 1:1 to receive birch pollen allergoid subcutaneous immunotherapy. Group I recieved four weekly injections and Group II recieved seven weekly injections.
Results: Mild-to-moderate treatment-related adverse events were reported for 57.7% of the patients (Group I: 36, Group II: 39). Tolerability was assessed by physicians and rated as ‘good’ or ‘very good’ for 55 patients in Group I and for 63 patients in Group II (94.0%). Levels of IgG and IgG4 (signs of inflammation) increased before and after treatment significantly in both groups.